Genfit SA (GNFT)
5.76
-0.12
(-2.04%)
USD |
NASDAQ |
Nov 04, 16:00
5.76
0.00 (0.00%)
After-Hours: 20:00
Genfit Total Liabilities (Quarterly): 117.09M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 104.42M |
| December 31, 2023 | 117.09M |
| June 30, 2023 | 129.74M |
| December 31, 2022 | 129.77M |
| June 30, 2022 | 133.59M |
| December 31, 2021 | 184.12M |
| June 30, 2021 | 120.37M |
| December 31, 2020 | 263.89M |
| June 30, 2020 | 252.85M |
| December 31, 2019 | 252.92M |
| June 30, 2019 | 258.86M |
| June 30, 2019 | 258.86M |
| December 31, 2018 | 238.55M |
| June 30, 2018 | 223.88M |
| June 30, 2018 | 223.88M |
| December 31, 2017 | 230.01M |
| June 30, 2017 | 31.01M |
| June 30, 2017 | 31.01M |
| December 31, 2016 | 24.76M |
| June 30, 2016 | 18.98M |
| Date | Value |
|---|---|
| June 30, 2016 | 18.98M |
| December 31, 2015 | 15.13M |
| June 30, 2015 | 14.95M |
| June 30, 2015 | 14.95M |
| December 31, 2014 | 19.38M |
| June 30, 2014 | 26.92M |
| June 30, 2014 | 26.92M |
| December 31, 2013 | 20.79M |
| June 30, 2013 | 21.22M |
| June 30, 2013 | 21.22M |
| December 31, 2012 | 22.15M |
| June 30, 2012 | 28.92M |
| June 30, 2012 | 28.92M |
| December 31, 2011 | 31.89M |
| June 30, 2011 | 33.13M |
| June 30, 2011 | 33.13M |
| December 31, 2010 | 30.59M |
| June 30, 2010 | 27.40M |
| December 31, 2009 | 32.76M |
| June 30, 2009 | 32.18M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
104.42M
Minimum
Jun 2024
263.89M
Maximum
Dec 2020
168.87M
Average
131.68M
Median
Total Liabilities (Quarterly) Benchmarks
| Edap TMS SA | 37.01M |
| DBV Technologies SA | 35.10M |
| Cellectis SA | 258.54M |
| Ascendis Pharma AS | 1.157B |
| Adaptimmune Therapeutics PLC | 225.43M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 192.20M |
| Shareholders Equity (Quarterly) | 75.11M |
| Debt to Equity Ratio | 0.9462 |
| Current Ratio | 2.940 |
| Net Debt Paydown Yield | -6.06% |